Acumen Pharmaceuticals (ABOS) director sells 32,300 shares after exercising options

Rhea-AI Filing Summary

Acumen Pharmaceuticals director Derrell Porter reported a series of option exercises and matching share sales in Common Stock. On June 15–17, 2026, he exercised options for a total of 19,500 shares at $1.07 per share and sold 32,300 shares in open-market transactions at weighted average prices around $2.32 per share, with individual trades ranging from $2.305 to $2.345. Following these transactions, Porter directly holds 35,500 shares of Acumen Pharmaceuticals Common Stock. The options exercised had vested in full on the date of the 2026 annual stockholder meeting.

Insights

Equity compensation and insider-trading analyst

Director exercised vested options for 19,500 shares and sold 32,300 shares, leaving a 35,500-share holding.

The filing shows Derrell Porter using vested stock options to acquire Acumen Pharmaceuticals Common Stock at a strike price of $1.07 per share, then selling more shares than he exercised at market prices around $2.32. This is a classic exercise-and-sell pattern, converting equity awards into cash.

Because total reported sales of 32,300 shares exceed the 19,500 shares acquired through exercises, Porter’s overall share position declined, though he still directly holds 35,500 shares. Trades were executed across multiple prices between $2.305 and $2.345, with no indication in the excerpt of a pre-arranged Rule 10b5-1 plan.

Insider Trade Summary

Net Seller: 32,300 shares ($75,240)

Net Sell 7 txns

Insider Porter Derrell

Role null

Sold 32,300 shs ($75K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	13,040	$0.00	--
Exercise	Common Stock	13,040	$1.07	$14K
Sale	Common Stock	13,040	$2.325	$30K
Sale	Common Stock	12,800	$2.326	$30K
Exercise	Stock Option (right to buy)	6,460	$0.00	--
Exercise	Common Stock	6,460	$1.07	$7K
Sale	Common Stock	6,460	$2.345	$15K

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 48,540 shares (Direct, null)

Footnotes (1)

1. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting.

Key Figures

Shares sold: 32,300 shares Exercise shares: 19,500 shares Market sale prices: $2.305–$2.345 per share +3 more

6 metrics

Shares sold 32,300 shares Common Stock sales on June 15–17, 2026

Exercise shares 19,500 shares Stock option exercises on June 15 and 17, 2026

Market sale prices $2.305–$2.345 per share Weighted average sales price range for Common Stock

Option exercise price $1.07 per share Conversion or exercise price of stock options

Shares held after 35,500 shares Direct Common Stock ownership following transactions

Option expiration June 4, 2035 Expiration date for exercised stock options

Key Terms

weighted average sales price, Stock Option (right to buy), annual stockholder meeting, open-market sale, +1 more

5 terms

weighted average sales price financial

"The price reported is a weighted average sales price."

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

annual stockholder meeting financial

"The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting."

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Porter Derrell

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MASSACHUSETTS 02465

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		M		6,460	A	$1.07	54,760	D
Common Stock	06/15/2026		S		6,460	D	$2.345	48,300	D
Common Stock	06/16/2026		S		12,800	D	$2.326(1)	35,500	D
Common Stock	06/17/2026		M		13,040	A	$1.07	48,540	D
Common Stock	06/17/2026		S		13,040	D	$2.325	35,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.07	06/15/2026		M			6,460	(2)	06/04/2035	Common Stock	6,460	$0	13,040	D
Stock Option (right to buy)	$1.07	06/17/2026		M			13,040	(2)	06/04/2035	Common Stock	13,040	$0	0	D

Explanation of Responses:

1. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions in ABOS stock did Derrell Porter report?

Derrell Porter reported exercising stock options and selling Acumen Pharmaceuticals (ABOS) Common Stock. He exercised options for 19,500 shares at $1.07 per share and sold 32,300 shares in open-market transactions at weighted average prices around $2.32 per share over June 15–17, 2026.

How many ABOS shares did Derrell Porter sell in the latest Form 4?

He sold a total of 32,300 Acumen Pharmaceuticals (ABOS) Common Stock shares. These open-market transactions occurred on June 15, 16, and 17, 2026, at weighted average prices ranging from $2.305 to $2.345 per share, as detailed in the Form 4 and its footnote.

What stock options did Derrell Porter exercise for Acumen Pharmaceuticals (ABOS)?

Porter exercised stock options covering 19,500 Acumen Pharmaceuticals (ABOS) shares at a conversion or exercise price of $1.07 per share. The options vested in full on the date of the 2026 annual stockholder meeting and were then exercised, according to the Form 4 disclosures.

How many ABOS shares does Derrell Porter hold after these transactions?

After the reported transactions, Derrell Porter directly holds 35,500 shares of Acumen Pharmaceuticals (ABOS) Common Stock. This figure reflects the net result of exercising 19,500 option shares and selling 32,300 shares in several open-market trades reported in the Form 4 filing.

At what prices were Derrell Porter’s ABOS share sales executed?

The reported prices are weighted averages for multiple trades, with sales ranging from $2.305 to $2.345 per Acumen Pharmaceuticals (ABOS) share. The Form 4 notes that detailed per-trade pricing within this range is available upon request from Porter, the company, or regulators.